OK Biotech Co., Ltd. (4155.TW) has a MoatMap StockRank of 69/100 based on Quality (52/100), Value (47/100), and Momentum (53/100) factor scores. The current signal is BUY. OK Biotech manufactures blood glucose monitoring systems. The blood glucose monitoring market is highly commoditized and dominated by massive global healthcare conglomerates, leaving OK Biotech with minimal pricing power or structural moat.
OK Biotech Co., Ltd. designs and manufactures blood glucose monitoring systems, test strips, and related diabetes management medical devices. The company benefits from high-volume, cost-competitive manufacturing capabilities and global regulatory certifications that enable extensive OEM/ODM partnerships. It operates as a highly focused niche exporter of diagnostic tools for the global healthcare market.
| Price | $0.49 |
| Market Cap | $67M |
| P/E (TTM) | 27.11 |
| Price/Book | 0.87 |
| Return on Equity | 5.2% |
| Return on Invested Capital | 3.5% |
| Debt/Equity | 38.46 |
| Gross Margin | 29.3% |
| Operating Margin | 15.7% |
| Revenue Growth | -6.9% |
| Dividend Yield | 2.0% |
| Free Cash Flow | $-13K |
OK Biotech Co., Ltd. operates in the Medical Devices industry, part of the Healthcare sector (Taiwan).